Zacks Investment Research Lowers Translate Bio (TBIO) to Sell

Zacks Investment Research lowered shares of Translate Bio (NASDAQ:TBIO) from a hold rating to a sell rating in a report issued on Saturday, Zacks.com reports.

According to Zacks, “Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. “

Several other research analysts also recently weighed in on the company. HC Wainwright reaffirmed a buy rating and set a $21.00 target price on shares of Translate Bio in a research note on Tuesday, April 9th. ValuEngine downgraded Translate Bio from a buy rating to a hold rating in a research note on Friday, December 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Translate Bio has a consensus rating of Buy and an average price target of $22.75.

Shares of NASDAQ:TBIO opened at $11.34 on Friday. Translate Bio has a 12-month low of $4.81 and a 12-month high of $16.60. The company has a market capitalization of $538.71 million and a price-to-earnings ratio of -3.09. The company has a debt-to-equity ratio of 0.83, a current ratio of 10.47 and a quick ratio of 10.47.

Translate Bio (NASDAQ:TBIO) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.09. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $0.80 million. On average, sell-side analysts anticipate that Translate Bio will post -1.52 EPS for the current year.

Hedge funds have recently made changes to their positions in the company. Barclays PLC raised its stake in shares of Translate Bio by 82.8% during the 4th quarter. Barclays PLC now owns 6,710 shares of the company’s stock worth $50,000 after buying an additional 3,039 shares during the period. Rhumbline Advisers acquired a new position in shares of Translate Bio during the 4th quarter worth approximately $77,000. Two Sigma Investments LP acquired a new position in shares of Translate Bio during the 4th quarter worth approximately $118,000. Teachers Advisors LLC acquired a new position in shares of Translate Bio during the 3rd quarter worth approximately $126,000. Finally, TIAA CREF Investment Management LLC acquired a new position in shares of Translate Bio during the 3rd quarter worth approximately $137,000. 59.27% of the stock is owned by institutional investors and hedge funds.

Translate Bio Company Profile

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Featured Story: Momentum Indicator: Relative Strength Index

Get a free copy of the Zacks research report on Translate Bio (TBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit